Asia Pacific Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type, Product, Application

The Asia Pacific cell line development market is expected to reach US$ 2,828.53million in 2027 from US$ 993.09million in 2019. The market is estimated to grow with a CAGR of 14.1% from 2020-2027.

The market growth is primarily driven by the increasing government participation in the cell line development projects and an upsurge in the development of the biotechnology industry. However, the susceptibility of cell lines toward contamination by various microorganisms hinders the market growth.

The Chinese government recognizes the country's potential in sustainable development, leading to leadership in the global biotechnology industry; therefore, it offers financial and regulatory assistance to predominantly support the research, development, and innovation strategies adopted by various companies. China has ~35 stem cell clinic research programs registered with the National Health Commission and the National Medical Products Administration. Along with various strategic industrial planning, the Chinese government is targeted development in recent years, particularly within the domestic biomedical sector, through strategic planning and research funding. In 2018, the Ministry of Science and Technology released the 2019 Annual Project Application Guide for Stem Cell and Transformation Research project. The government projected financing US$ 58 million (400 million Yuan) to support stem cell research. Two of the 22 nationally funded stem cell clinical research projects are correlated to c-kit cells.

Further, the government of South Korea has invested a substantial amount in the launch of various projects. According to an article published in Business Korea in August 2018, the government ministries - including the Ministry of Health and Welfare (MOHW); Ministry of Science and ICT (MSIT); and Ministry of Trade, Industry, and Energy (MOTIE) - were looking forward to launching a project named as National New Drug Development Support Project. It has invested ~US$ 1.78 billion (KRW 2 trillion) in this project. Hence, such high government investments drive the cell line development market growth in Asia Pacific countries.

The COVID-19 pandemic, leading to uncertainties around economic recovery, has affected the growth of the pharmaceutical industry in Asia Pacific. Cell lines are widely used in the development of various pharmaceuticals and biologics, as well as in applications such as drug screening, cell-based assay development, functional gene studies, diagnostics, and tissue engineering. Cell line development is crucial for examining the efficiency and toxicity of drugs in vitro. It reduces time, effort and cost, and minimizes the chance of drug failure in the clinical trial stage that involves the production of recombinant proteins such as monoclonal antibodies, growth factors, enzymes, and the novel approach of developing immunotherapy to treat cancer using a wide variety of expression systems. In the last few years, the collaboration between cell line developers or manufacturers and novel therapeutics companies has boosted the expansion of the cell-line development market. However, the pandemic has gathered the major attention toward the drug and vaccine development against the novel coronavirus, leading to the temporary suspension of other research activities.

On the basis of type, the North America cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segments held the largest market share in 2019, whereas the hybridomas segment is anticipated to register the highest CAGR in the market during the forecast period. The North America cell line development market, by product, is segmented into equipment, and media and reagents. The media & reagent segment held a larger share of the market in 2019, and it is anticipated to register a higher CAGR in the market from 2020 to 2027. Based on application, the North America cell line development market is segmented into drug discovery, bioproduction, and tissue engineering. The bioproduction segment held the largest market share in 2019. However, the drug discovery segment is anticipated to register the highest CAGR in the market during 2020-2027.

The Chinese Academy of Sciences (CAS) and National Stem Cell Foundation of Australia (NSCFA) are among the primary and secondary sources referred to while preparing the report on the Asia Pacific cell line development market.